Recurrent eczema herpeticum - a retrospective European multicenter study evaluating the clinical characteristics of eczema herpeticum cases in atopic dermatitis patients.
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
received:
11
08
2019
accepted:
24
10
2019
pubmed:
17
11
2019
medline:
15
5
2021
entrez:
17
11
2019
Statut:
ppublish
Résumé
Eczema herpeticum (EH) is a disseminated viral infection of eczematous skin disease with the herpes simplex virus. Knowledge on clinical characteristics, risk factors and recurrent disease is limited. Our aim was to better define clinical characteristics and risk factors for EH and especially for recurrent EH. A retrospective analysis of EH cases assessed the history, clinical signs, prior treatment and laboratory results using a predefined questionnaire. A total of 224 EH cases from eight European centres were included. Extrinsic AD was identified as risk factor for EH, and only one patient suffered from intrinsic AD. Early onset of AD was identified as risk factor for recurrent EH. Pretreatment with topical steroids, systemic steroids, topical calcineurin inhibitors or plain emollients reflected standard therapy. Many patients showed AD lesions without EH, but skin without AD lesions was never affected by herpetic lesions. Patients with clinically active, extrinsic AD are at risk of EH. Recurrent EH is associated with confounders of severe atopic distortion and requires active AD lesions for clinical manifestation. Recurrent eczema herpeticum mainly affects patients with early onset of AD.
Sections du résumé
BACKGROUND
BACKGROUND
Eczema herpeticum (EH) is a disseminated viral infection of eczematous skin disease with the herpes simplex virus. Knowledge on clinical characteristics, risk factors and recurrent disease is limited. Our aim was to better define clinical characteristics and risk factors for EH and especially for recurrent EH.
METHODS
METHODS
A retrospective analysis of EH cases assessed the history, clinical signs, prior treatment and laboratory results using a predefined questionnaire.
RESULTS
RESULTS
A total of 224 EH cases from eight European centres were included. Extrinsic AD was identified as risk factor for EH, and only one patient suffered from intrinsic AD. Early onset of AD was identified as risk factor for recurrent EH. Pretreatment with topical steroids, systemic steroids, topical calcineurin inhibitors or plain emollients reflected standard therapy. Many patients showed AD lesions without EH, but skin without AD lesions was never affected by herpetic lesions.
CONCLUSION
CONCLUSIONS
Patients with clinically active, extrinsic AD are at risk of EH. Recurrent EH is associated with confounders of severe atopic distortion and requires active AD lesions for clinical manifestation. Recurrent eczema herpeticum mainly affects patients with early onset of AD.
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1074-1079Informations de copyright
© 2019 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.
Références
Wollenberg A. Eczema herpeticum. Chem Immunol Allergy 2012; 96: 89-95.
Sanderson IR, Brueton LA, Savage MO, Harper JI. Eczema herpeticum: a potentially fatal disease. Br Med J (Clin Res Ed) 1987; 294: 693-694.
Aronson P, Yan C, Mittal M, Mohamad Z, Shah S. Delayed acyclovir outcome. Pediatrics 2011; 128: 1161-1167.
Wollenberg A, Oranje A, Deleuran M et al. ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients. J Eur Acad Dermatol Venereol 2016; 30: 729-747.
Leung DY. Why is eczema herpeticum unexpectedly rare? Antiviral Res 2013; 98: 153-157.
Yoon M, Spear PG. Disruption of adherens junctions liberates nectin-1 to serve as receptor for herpes simplex virus and pseudorabies virus entry. J Virol 2002; 76: 7203-7208.
De Benedetto A, Slifka MK, Rafaels NM et al. Reductions in claudin-1 may enhance susceptibility to herpes simplex virus 1 infections in atopic dermatitis. J Allergy Clin Immunol 2011; 128: 242-246. e5.
Wollenberg A, Wagner M, Gunther S et al. Plasmacytoid dendritic cells: a new cutaneous dendritic cell subset with distinct role in inflammatory skin diseases. J Invest Dermatol 2002; 119: 1096-1102.
Leung DY, Gao PS, Grigoryev DN et al. Human atopic dermatitis complicated by eczema herpeticum is associated with abnormalities in IFN-gamma response. J Allergy Clin Immunol 2011; 127: 965-973. e1-5.
Howell MD, Wollenberg A, Gallo RL et al. Cathelicidin deficiency predisposes to eczema herpeticum. J Allergy Clin Immunol 2006; 117: 836-841.
Traidl S, Kienlin P, Begemann G et al. Patients with atopic dermatitis and history of eczema herpeticum elicit herpes simplex virus-specific type 2 immune responses. J Allergy Clin Immunol 2018; 141: 1144-1147. e5.
Yoshida M, Umene K. Close association of predominant genotype of herpes simplex virus type 1 with eczema herpeticum analyzed using restriction fragment length polymorphism of polymerase chain reaction. J Virol Methods 2003; 109: 11-16.
Bork K, Brauninger W. Increasing incidence of eczema herpeticum: analysis of seventy-five cases. J Am Acad Dermatol 1988; 19: 1024-1029.
Beck LA, Boguniewicz M, Hata T et al. Phenotype of atopic dermatitis subjects with a history of eczema herpeticum. J Allergy Clin Immunol 2009; 124: 260-269, 9. e1-7.
Wollenberg A, Zoch C, Wetzel S, Plewig G, Przybilla B. Predisposing factors and clinical features of eczema herpeticum: a retrospective analysis of 100 cases. J Am Acad Dermatol 2003; 49: 198-205.
Dekio I, Chinuki Y, Furumura M, Morita E. Recurrent Kaposi's varicelliform eruption successfully controlled by low-dose oral valaciclovir. J Dermatol 2012; 39: 197-199.
Komericki P, Akkilic M, Kranke B, Aberer W. Recurrent herpes simplex infection in multiple locations in an otherwise healthy boy. Pediatr Dermatol 2010; 27: 113-114.
Ambo M. Relapsing Kaposi's varicelliform eruption and herpes simplex following facial tacrolimus treatment for atopic dermatitis. Acta Derm Venereol 2002; 82: 224-225.
Latta RA, Baker DA. Treatment of recurrent eczema herpeticum in pregnancy with acyclovir. Infect Dis Obstet Gynecol 1996; 4: 239-242.
Schmid-Grendelmeier P, Simon D, Simon HU, Akdis CA, Wuthrich B. Epidemiology, clinical features, and immunology of the “intrinsic” (non-IgE-mediated) type of atopic dermatitis (constitutional dermatitis). Allergy 2001; 56: 841-849.
Rajka G, Langeland T. Grading of the severity of atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 1989; 144: 13-14.
European Task Force on Atopic Dermatitis. Severity scoring of atopic dermatitis: the SCORAD index. Dermatology 1993; 186: 23-31.
Wollenberg A, Barbarot S, Bieber T et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol 2018; 32: 657-682.
Luca NJ, Lara-Corrales I, Pope E. Eczema herpeticum in children: clinical features and factors predictive of hospitalization. J Pediatr 2012; 161: 671-675.
Akdis M, Simon HU, Weigl L, Kreyden O, Blaser K, Akdis CA. Skin homing (cutaneous lymphocyte-associated antigen-positive) CD8+ T cells respond to superantigen and contribute to eosinophilia and IgE production in atopic dermatitis. J Immunol 1999; 163: 466-475.
Cabon N, Ducombs G, Mortureux P, Perromat M, Taieb A. Contact allergy to aeroallergens in children with atopic dermatitis: comparison with allergic contact dermatitis. Contact Dermatitis 1996; 35: 27-32.
Schafer T, Kramer U, Vieluf D, Abeck D, Behrendt H, Ring J. The excess of atopic eczema in East Germany is related to the intrinsic type. Br J Dermatol 2000; 143: 992-998.
Salt BH, Boguniewicz M, Leung DY. Severe refractory atopic dermatitis in adults is highly atopic. J Allergy Clin Immunol 2007; 119: 508-509.
Peng WM, Jenneck C, Bussmann C et al. Risk factors of atopic dermatitis patients for eczema herpeticum. J Invest Dermatol 2007; 127: 1261-1263.
Werfel T, Allam JP, Biedermann T et al. Cellular and molecular immunologic mechanisms in patients with atopic dermatitis. J Allergy Clin Immunol 2016; 138: 336-349.
David TJ, Longson M. Herpes simplex infections in atopic eczema. Arch Dis Child 1985; 60: 338-343.
Aronson PL, Shah SS, Mohamad Z, Yan AC. Topical corticosteroids and hospital length of stay in children with eczema herpeticum. Pediatr Dermatol 2013; 30: 215-221.
Takahashi R, Sato Y, Kurata M, Yamazaki Y, Kimishima M, Shiohara T. Pathological role of regulatory T cells in the initiation and maintenance of eczema herpeticum lesions. J Immunol 2014; 192: 969-978.
Kohwoon K, Junseok K, Sung W, Myongson S. Relationship between the presence of eczema herpeticum and the significance of clinical and laboratory tests in Korean children with atopic dermatitis. Iran J Pediatr 2016; 4: 4683.
Sohail M, Khan FA, Shami HB, Bashir MM. Management of eczema herpeticum in a Burn Unit. J Pak Med Assoc 2016; 66: 1357-1361.
Tupe CL, Weiler BA, Verceles AC, McCurdy MT. A fatal case of eczema herpeticum with septic shock due to methicillin-resistant Staphylococcus aureus. Am J Crit Care 2016; 25: 379-382.
Wetzel S, Wollenberg A. Eczema herpeticatum. Hautarzt 2004; 55: 646-652.